Frontage Expands Bioanalytical Capacity and Capabilities

Published on: 

The company is expanding its bioanalytical capacity and capabilities to support biologic drug development, cell and gene therapy development, and biomarker analysis.

Frontage Laboratories, a contract research organization, is now operating with expanded bioanalytical laboratories at its Exton, PA, site. In early October 2019, the company added 10,000 ft2 of laboratory space to support biologic drug and cell and gene therapy development as well as biomarker analysis.

In addition, the company will establish a center of excellence for cell and gene therapies that will include dedicated labs in DNA separation, purification, flow cytometry, and cell culture. The expansion will also provide greater biomarker, pharmacokinetic, and immunogenicity bioanalytical capacity to support large Phase II-IV studies.

As part of the expansion, support services are also being enhanced, including sample management and sample storage space. Instrument capacity for liquid chromatography with tandem mass spectrometry and inductively coupled plasma mass spectrometry is also being expanded to support both large- and small-molecule as well as elemental analysis. The expansion is scheduled for completion in the fourth quarter of 2019.


“The expansion will provide our customers with enhanced bioanalytical capacity to support their large-scale clinical trials. This investment will allow us to enhance our support for new therapeutic platforms such as cell and gene therapy,” said John Lin, PhD, executive vice-president, Frontage Global Bioanalytical Services, in a company press release.

Source: Frontage Laboratories